Nuvectis Pharma, Inc. NVCT Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s other commercial liabilities?
- Nuvectis Pharma, Inc. (NVCT) reported other commercial liabilities of $36K in Q1 2026.
- How has Nuvectis Pharma, Inc.'s other commercial liabilities changed year-over-year?
- Nuvectis Pharma, Inc.'s other commercial liabilities decreased by 95.8% year-over-year, from $865K to $36K.
- What is the long-term trend for Nuvectis Pharma, Inc.'s other commercial liabilities?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s other commercial liabilities has grown at a -26.5% compound annual growth rate (CAGR), from $395K to $115K.